Simon Fraser - Smith Nephew President - Advanced Wound Management

SNNUF Stock  USD 12.31  0.40  3.15%   

President

Mr. Simon Fraser is President Advanced Wound Management of the Company. He Joined Smith Nephew in January 2019 with commercial leadership responsibility for Advanced Wound Management in the US and global upstream marketing for the Advanced Wound Management Franchise. As part of his executive responsibilities Simon will also provide leadership for Healthcare Systems. Simon is based in Fort Worth, US. Skills and Experience Simon brings to this role more than 25 years of experience across medical devices, pharmaceuticals and diagnostics, including wound management. Importantly, he is a purposedriven and accomplished business leader who has successfully managed large, global commercial organisations with full PL responsibility while growing business and earning market share. Prior to joining Smith Nephew Simon was Group Vice President of DentsplySironas Dental Implant Global Business Unit. Prior to this Simon was Vice President, US Commercial Infectious Diseases including corporate accounts at Abbott Laboratories. Simon joined Abbott following the acquisition of Alere where he had three successful years as the President of Latin America. Prior to these roles, Simon had a 15year career with Johnson Johnson, where he held increasingly senior commercial roles spanning surgical devices, wound management, implants and pharmaceuticals including both global strategic marketing and PL responsibilities. since 2019.
Age 50
Tenure 5 years
Phone44 1923 477 100
Webhttps://www.smith-nephew.com

Smith Nephew Management Efficiency

The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 2.71 B in total debt with debt to equity ratio (D/E) of 0.54, which is about average as compared to similar companies. Smith Nephew Plc has a current ratio of 1.74, which is within standard range for the sector. Debt can assist Smith Nephew until it has trouble settling it off, either with new capital or with free cash flow. So, Smith Nephew's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Smith Nephew Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Smith to invest in growth at high rates of return. When we think about Smith Nephew's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Jonathan MonsonBoston Scientific Corp
N/A
Kathryn FinkStryker
48
Thomas FrinziAbbott Laboratories
60
Hubert AllenAbbott Laboratories
58
Catherine SzymanEdwards Lifesciences Corp
54
Sian RobertsAlign Technology
N/A
Lonny CarpenterStryker
55
Chad PhippsZimmer Biomet Holdings
52
David PierceBoston Scientific Corp
57
Joseph CucoloZimmer Biomet Holdings
55
Glenn BoehnleinStryker
62
Karen PrangeBoston Scientific Corp
52
Robert MarshallZimmer Biomet Holdings
N/A
FinkStryker
47
Bradley LermanMedtronic PLC
63
William BerryStryker
58
Heather MasonAbbott Laboratories
56
Michael PhalenBoston Scientific Corp
56
Lanny RoperDexCom Inc
50
Scott UllemEdwards Lifesciences Corp
57
Julie TayAlign Technology
51
Smith Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. Smith Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Smith Nephew operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 18000 people. Smith Nephew Plc [SNNUF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Smith Nephew Plc Leadership Team

Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Namal Nawana, CEO, Executive Director
Michael Friedman, Non-Executive Independent Director
Diogo MoreiraRato, President - Europe and Canada
Alison Parkes, Chief Officer
Skip Kiil, President - Orthopedics
Erik Engstrom, Non-Executive Director
Deepak Nath, CEO Director
Matthew Stober, President - Global Operations
Marc Owen, Non-Executive Director
AnneFrancoise Nesmes, CFO Director
Helen Barraclough, Company Counsel
Rodrigo Bianchi, President IRAMEA
Brian Larcombe, Senior Independent Non-Executive Director
Elga Lohler, Chief Human Resource Officer
Bradley Cannon, Sports Orthopaedics
Gunthorp Oie, IR Contact Officer
Roland Diggelmann, Non-Executive Director
Helen Maye, Chief Human Resources Officer
Vinita Bali, Non-Executive Director
Simon Fraser, President - Advanced Wound Management
Massimiliano Colella, President Europe - Middle East and Africa
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee
Graham Baker, CFO, Executive Director
Cathy ORourke, Chief Legal and Compliance Officer
Roberto Quarta, Non-Executive Independent Chairman of the Board
Joe Metzger, VP Communications
Cyrille Petit, Chief Corporate Development Officer
Julie Brown, CFO, Director and Member of Disclosures Committee
Glenn Warner, President - Advanced Wound Management
Robin Freestone, Non-Executive Director
Paul Connolly, Pres Operations
Virginia Bottomley, Non-Executive Independent Director
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs
Angie Risley, Non-Executive Director
Mark Gladwell, President - Global Operations
Andrew Swift, VP Relations
Vasant Padmanabhan, President - Research & Development
Michael Frazzette, President - Advanced Surgical Devices
Joseph Papa, Non-Executive Independent Director
Ingeborg Oie, VP, Investor Relations
Susan Swabey, Company Secretary
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer
Philip Cowdy, Chief Officer
Gordon Howe, President of Global Operations
John Campo, Chief Legal Officer
Brad Cannon, President Europe and Canada
Ian Barlow, Non-Executive Independent Director
Catheryn ORourke, Chief Legal Officer

Smith Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Smith Pink Sheet analysis

When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.